Taking into account these inherent limitations, our findings suggest that risk stratification based on clinical-pathological factors, such as tumor grade, Ki67, ER, and PgR, could be useful in personalizing treatment according to patient menopausal status. This evidence concerns the gene MKI67 and neoplasm.